This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
Dr Gopi Gnanasegaran
In this short introductory video, Dr Gopi Gnanasegaran introduces session 2 of the PRRT Masterclass 2021.
//-->Ivy Vito
In this 20-minute masterclass, Mrs Vito shares best practice from the Royal Free Hospital for 177 Lu-oxodotreotide treatment, focusing on the treatment...
PRRT: revisiting the Lutathera® ([177Lu]Lu-oxodotreotide) SmPC
Dr Gopinath Gnanasegaran
Dr Gopinath Gnanasegaran, Consultant in Nuclear Medicine at the...
Treatment administration
This video explains the process of administration of LUTATHERA ® using the gravity method, including adequate handling...
Dr Gopinath Gnanasegaran
In this 20-minute masterclass, Dr Gnanasegaran provides an overview of the rationale and utility of molecular...
Richard Meades
In this 30-minute masterclass, Richard Meades explores the fundamental radioactive characteristics of lutetium-177,...
Dr John Buscombe
Dr John Buscombe, Locum Consultant Physician in Nuclear Medicine at Barts...
NETTER-1 update and case presentations
Dr Alia Munir
Dr Alia Munir, Consultant Endocrinologist at Sheffield Teaching Hospitals NHS Foundation Trust ,...